Final psychedelics guidance suggests FDA is 'receptive' to helping companies succeed
The agency’s finalized recommendations for clinical testing of psychedelic compounds for mental health could pave the way for companies like Compass Pathways, whose psilocybin-based therapy for…
Read the full articleYou might also wanna read
Synthetic Psilocybin Shows Strong Results in Treatment-Resistant Depression Trials
Regulators are now mulling the results of the late-stage trial
economist.com·4mo agoThe future of US psychedelic medicine is carved out by the FDA
The US Food and Drug Administration (FDA) has issued its first comprehensive guidance on how psychedelic drugs should best be studied in cli
While the FDA finalizes how to test drugs it treats like heroin, Mass. eyes psychedelic therapy
FDA finalized new guidance for testing MDMA and psilocybin in trials, days after Massachusetts advanced its own psychedelic therapy pilot.
The debate about whether the NHS should use magic mushrooms to treat depression
Many clinical trials to test the use of psychedelic medicines for conditions such as depression have been underway since 2022 - with surpris
Real-World Study Shows Psilocybin Improves Treatment-Resistant Depression Symptoms
One of the first real-world studies of psilocybin therapy suggests meaningful improvements in treatment-resistant depression outside the con
mdsc.pe·19d agoFDA Fast-Tracks Psychedelic-Based Mental Health Treatments as Aging America Faces Rising Long-Term Care Risk
Federal regulators are accelerating psychedelic-based mental health treatments for serious conditions. Many veterans, researchers, and patie
Comments
Sign in to join the conversation.
No comments yet. Be the first.